Semantic Hub is a service that uses the capabilities of artificial intelligence (AI) to identify the potential of drug candidates. The service collects up to a million documents on the desired topic (scientific articles, descriptions of clinical research, patents, press releases, etc.), conducts their deep semantic analysis, compares the results from various sources and generates a report for the pharmaceutical company, which reflects the most objective assessment of the potential of "candidates for drugs" taking into account all risk factors and competitive advantages.
Semantic Hub accelerates the assessment of promising developments and reduces the risk of drug failure due to missing important information up to 30%.
2021: FRII sold a stake in SemanticHub
On October 12, 2021, it became known about the sale of the entire stake in Semantic Hub, owned by the Internet Initiatives Development Fund (FRII). It was bought by the founders of the company and investor Valentin Doronichev. According to the results of this transaction, only individuals began to be among the shareholders of the AI system developer for the pharmaceutical industry: about 64.5% of faunders and about 35.5% of investors. It follows from the base of Kontur.Focus that Valentin Doronichev increased his share from 17.83% to 31.73%.
 | We are glad that we have grown enough to buy back the share of FRII. And it is especially pleasant that our investors, who have been with us from the very beginning, continue to believe in us. This suggests that we are on the right track, "said Irina Efimenko, founder and CEO of Semantic Hub, whose words are quoted by the company's press service. |  |
According to her, FRII gave the startup not only investments, but also expertise in how to build an innovative company at an early stage. Efimenko noted that the international market has become the main one for Semantic Hub, and industry expertise and international relations in the Big Pharma world have gained the greatest importance for the company, she added.
By October 2021, the geography of Semantic Hub projects covers more than 30 countries of the world, including the USA and Canada, China, India, South Africa, Japan, South Korea, etc.
Director of the IIDF accelerator Dmitry Kalaev says that the fund left Semantic Hub "with a good rate of profitability." On what financial conditions the FRII sold a stake in a startup is not specified.
According to Kalaev, by October 2021, the most pressing task for the fund is the entry of startups into global markets.
| | We reoriented all acceleration and support programs, our venture capital division and investments to this activity, "he stressed. | |
2017: Investments of 24 million rubles
On August 17, 2017, the Foundation for the Development of Internet Initiatives (FRII) announced its investment in the startup Semantik Hub. The volume of investments amounted to 24 million rubles. In addition to FRII, businessmen Valentin Doronichev and Vladimir Preobrazhensky took part in the deal.
The raised funds in the startup are planned to be directed to marketing and sales in Russia and abroad, as well as to research and development. The company is working on the fact that the service could adapt to the requirements of customers with minimal time and money costs.
According to Irina Efimenko, head of Semantik Hub, the service is ready to scale in world markets, primarily in European and Chinese.
| | Access to the expertise of international companies will allow adapting Semantik Hub software modules to tasks of any complexity. In this case, we can talk about absolute leadership in the market for semantic analysis for pharmaceutical companies, "she said. | |
According to the FRII, R&D costs in pharmaceuticals and biotechnology are the largest among other markets. The volume of investments in this area reached $157 billion in 2016. By August 2017, the industry has approximately 7.3 thousand biotech and pharmaceutical companies, as well as about 300 venture funds.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |